There is no milestone payment for FDA approval of generic Lovenox. There are, however, $163M in potential milestone payments from NVS triggered by Lovenox sales thresholds and Copaxone regulatory goals and sales thresholds (#msg-44687884).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”